All In Biotech

Drug Trial Radar · NCT03888716

A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

A Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 After a Single and Multiple Ascending Oral Doses in Healthy Subjects and Patients With Primary Mitochondrial Disease

Last checked: Nov 19, 2026Latest source record: Oct 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Mar 18, 2019

Primary completion

Mar 16, 2021

Study completion Mar 16, 2021

Sponsor

Lead sponsor
Abliva ABIndustry
Sponsor type
Industry
First posted
Mar 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C. Part A and Part B include healthy volunteers only and will be completed before Part C including patients with primary mitochondrial disease will be initiated. The starting dose in the first cohort of Part A will be 25 mg. The dose level in the additional cohorts will be decided following review of data of the previous cohorts.

Conditions

  • Mitochondrial Diseases
  • Mitochondrial Respiratory Chain Deficiencies
  • MELAS Syndrome
  • Mitochondrial Myopathies

Interventions

  • KL1333Drug

    25 and 100 mg KL1333 encapsulated tablets

  • Placebo Oral TabletDrug

    25 and 100 mg placebo encapsulated tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: incidence and severity of AEsTime frame: Day 15
  2. Safety: incidence of laboratory abnormalities, based on haematology, clinical chemistry, and urinalysis test resultsTime frame: Day 15
  3. Safety: 12 lead ECG parametersTime frame: Day 15
  4. Safety: Number of participants with clinically significant abnormal vital signs measurementsTime frame: Day 15
  5. Safety: Number of participants with clinically significant abnormal physical examinationsTime frame: Day 15

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • UCL

    London, United Kingdom

  • Covance Leeds

    Leeds, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.